Temasek Holdings Updates Passive Stake in Beam Therapeutics

TL;DR

**Temasek Holdings still holds a big chunk of Beam Therapeutics, signaling long-term confidence.**

AI Summary

Temasek Holdings (Private) Ltd, a Singaporean investment company, filed an amended SC 13G/A on February 6, 2024, indicating a change in its ownership of Beam Therapeutics Inc. common stock as of December 31, 2023. This filing updates their previous disclosure, showing their continued significant, though passive, investment in Beam Therapeutics. This matters to investors because Temasek is a major institutional investor, and their continued stake signals confidence in Beam Therapeutics' long-term prospects, potentially influencing other investors.

Why It Matters

This filing shows that a major institutional investor, Temasek Holdings, continues to hold a significant stake in Beam Therapeutics, which can be seen as a vote of confidence in the company's future.

Risk Assessment

Risk Level: low — This filing is an update to a passive investment, indicating no immediate change in company control or strategy.

Analyst Insight

Investors should note that a major institutional investor like Temasek Holdings continues to hold a stake in Beam Therapeutics, which could be a positive long-term signal, but this filing itself doesn't suggest any immediate action beyond monitoring future disclosures.

Key Players & Entities

• Temasek Holdings (Private) Ltd (company) — the reporting person and institutional investor
• Beam Therapeutics Inc. (company) — the subject company whose securities are being reported
• December 31, 2023 (date) — the date of the event requiring the filing
• February 6, 2024 (date) — the filing date of the SC 13G/A
• 07373V105 (number) — the CUSIP number for Beam Therapeutics Inc. Common Stock

Forward-Looking Statements

• Temasek Holdings will maintain a significant, passive stake in Beam Therapeutics for the foreseeable future. (Temasek Holdings (Private) Ltd) — high confidence, target: December 31, 2024

FAQ

Key Financial Figures

• $0.01 — me of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securiti

Filing Documents

• d737211dsc13ga.htm (SC 13G/A) — 40KB
• 0001193125-24-024797.txt ( ) — 42KB

From the Filing

SC 13G/A 1 d737211dsc13ga.htm SC 13G/A SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Beam Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 07373V105 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No.07373V105 Page 2 of 5 1 NAMES OF REPORTING PERSONS Temasek Holdings (Private) Limited 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)(b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Republic of Singapore NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 3,076,117 (1) 7 SOLE DISPOSITIVE POWER 0 8 SHARED DISPOSITIVE POWER 3,076,117 (1) 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,076,117 (1) 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.8% (1) (2) 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC (1) See Item 4. (2) Based on 81,504,057 shares of the Issuers common stock outstanding as of November 1, 2023, as set forth in the Issuers (as defined herein) quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the Commission) on November 8, 2023. CUSIP No.07373V105 Page 3 of 5 Item1(a). Name of Issuer: Beam Therapeutics Inc. (the Issuer) Item1(b). Address of Issuers Principal Executive Offices: 238 Main Street, Cambridge, MA 02142 Item2(a). Name of Person Filing: Temasek Holdings (Private) Limited (Temasek) Item2(b). Address of Principal Business Office or, if none, Residence: 60B Orchard Road, #06-18 Tower 2, The Atrium@Orchard, Singapore 238891 Item2(c). Citizenship: Republic of Singapore Item2(d). Title of Class of Securities: Common Stock, par value $0.01 per share. Item2(e). CUSIP Number: 07373V105 Item3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: Not applicable. Item4. (a) Amount beneficially owned: As of the date hereof, Temaseks indirect wholly-owned subsidiaries directly owned an aggregate of 3,076,117 shares of the Issuers common stock. Accordingly, as of the date hereof Temasek may be deemed to beneficially own the 3,076,117 shares of the Issuers common stock collectively owned by its indirect wholly-owned subsidiaries. (b) Percent of class: As of the date hereof: 3.8% The percentages above are based on 81,504,057 shares of the Issuers common stock outstanding as of November 1, 2023, as set forth in the Issuers quarterly report on Form 10-Q filed with the Commission on November 8, 2023. (c) Number of shares as to which the person has: With respect to the shared power to vote, or to direct the vote, and to dispose, or to direct the disposition of, the shares of the Issuers common stock, please see Item 4(a) above regarding qualifications as to beneficial ownership. (i) Sole power to vote or to direct the vote: 0. (ii) Shared power to vote or to direct the vote: 3,076,117 (iii) Sole power to dispose or to direct the disposition of: 0. (iv) Shared power to dispose or to direct the disposition of: 3,076,117 CUSIP No.07373V105 Page 4 of 5 Item5. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following . Item6. Not Applicable. Item7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable. Item8. Identification and Classification of Members of the Group. Not Applicable. Item9. Notice of Dissolution of Group. Not Applicable. Item10. Certification. By signing below I certify that, to the best of